LYEL News and Press, Lyell Immunopharma Inc. From 03/05/24

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced that three abstracts of new nonclinical data have ...

On track to report initial clinical and translational data from lead CAR T-cell and TIL product candidates in 2024 Received Orphan Drug Designation for LYL845 for the treatment of melanoma Expect to submit IND for second generation ROR1-targeted CAR T-cell product in the first half of 2...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team wi...

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that members of its senior management team wi...

2023-11-16 22:53:14 ET Summary The Russell 2000 had a "Power Day" with a return of 5.48%, leading some to speculate that the bottom is in for small and microcaps. Power Days, where the index returns 5% or higher in a single day, are rare and tend to occur in clusters. Historic...

2023-11-10 14:23:48 ET Summary Lyell Immunopharma results from a phase 1 study using LYL797 for the treatment of relapsed/refractory NSCLC and TNBC patients with ROR1 expression expected in the 1st half of 2024. Results from phase 1 study using LYL845 for the treatment of patients...

2023-11-09 17:32:29 ET More on Lyell Immunopharma Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data JP Morgan cuts Lyell to neutral, pending data for cell therapy platform Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earn...

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S. Food and Drug Administration (F...

Lyell Immunopharma Inc. (LYEL) is expected to report $-0.27 for Q3 2023